Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

102

Participants

Timeline

Start Date

September 21, 2022

Primary Completion Date

June 25, 2024

Study Completion Date

December 30, 2025

Conditions

Advanced KRAS G12D Mutant Solid Tumors

Interventions

DRUG

HRS-4642

HRS-4642 will be administrated per dose level in which the patients are assigned.

Trial Locations (1)

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY